UK-based MiroBio, an Oxford Science Enterprises portfolio company, to be acquired by US-based Gilead Sciences
Oxford Science Enterprises (OSE), an Oxford-based investment firm that uniquely supports startups with its partnership with the University of Oxford, announced on Thursday that its life sciences portfolio company, MiroBio, is set to be acquired by US-based biopharmaceutical company Gilead Sciences for $405M (approximately €396M) in cash.